BioVie Unveils Phase 2 Trial Design for Long COVID Neurological Symptoms Treatment
BioVie Inc. is leveraging its experience in neuroinflammation to target the Long COVID market with bezisterim, an oral anti-inflammatory...
BioVie Inc. is leveraging its experience in neuroinflammation to target the Long COVID market with bezisterim, an oral anti-inflammatory...
Creative Medical Technology Holdings (CELZ) has received FDA Fast Track designation for CELZ-201-DDT, its allogeneic perinatal cell therapy for...
Tiziana Life SciencesLife Sciences has received FDA clearance for a Phase 2a trial of intranasal foralumab in patients with...
IO Biotech’s Phase 3 trial of Cylembio plus pembrolizumab in advanced melanoma narrowly missed statistical significance on its primary...
FoRx Therapeutics has dosed the first patient in a Phase 1 trial of FORX-428, an oral PARG inhibitor, in...
The FDA accepted Arvinas and Pfizer’s New Drug Application (NDA) for vepdegestrant, an oral PROTAC estrogen receptor degrader, for...
Dogwood Therapeutics announced enrollment of the first 50 patients in its Phase 2b trial of Halneuron for chemotherapy-induced neuropathic...
Inadequate disease control remains a persistent challenge in the management of idiopathic inflammatory myopathies (IIM), particularly for dermatomyositis (DM)...
A propensity-matched analysis of 410 liver transplant patients from the GUARDIAN-Liver Registry showed a 51% reduction in early allograft...
PharmAla Biotech has delivered over 500 capsules of its LaNeo 40mg MDMA to the Merhavim Mental Health Centre in...